Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma

John S Chan MD¹, Robert L Cowie MD¹, Gerald C Lazarenko MD², Cinde Little RRT¹, Sandra Scott RRT¹, Gordon T Ford MD FCCP¹

¹Division of Respiratory Medicine and ²Department of Emergency Medicine, University of Calgary, Calgary, Alberta

OBJECTIVE: To compare the relapse rate after a single intramuscular injection of a long acting corticosteroid, betamethasone, with oral prednisone in patients discharged from the emergency department (ED) for acute exacerbations of asthma.

PATIENTS AND METHODS: Patients with acute exacerbations of asthma who were suitable for discharge from the ED were enrolled in a double-blind, randomized, placebo controlled pilot study. At discharge, patients were randomly assigned to receive either intramuscular betamethasone 12 mg and placebo capsules, or a placebo intramuscular injection and prednisone 50 mg daily for seven days. At days 7 and 21, patients were contacted by telephone to determine relapse. Relapse was defined as an unscheduled visit to a physician for treatment of continuing or worsening symptoms of asthma.

RESULTS: One hundred and seventy-one patients were enrolled, of whom 87 were randomly assigned to the betamethasone group and 84 to the prednisone group. Baseline characteristics were matched evenly between the groups, with the exception of asthma duration (15.5 versus 21.2 years, respectively) and use of inhaled corticosteroids (46% versus 64.3% respectively) (P<0.05). Using intention-to-treat analysis, the relapse rates for betamethasone and prednisone at day 7 were 14.9% (13 of 87 patients) and 25% (21 of 84 patients), respectively (P=0.1), and at day 21, the rates were 36.8% (32 of 87 patients) and 31% (26 of 84 patients), respectively (P=0.4). There were no differences in symptom score, peak flows and adverse effects between the two groups at days 7 and 21.

CONCLUSIONS: A single dose of intramuscular betamethasone 12 mg was safe and as efficacious as prednisone in preventing the relapse of acute asthma. There was a trend toward a reduced relapse rate at seven days. In select ED patients discharged for acute asthma, intramuscular betamethasone may be an effective alternative to prednisone.

Key Words: Asthma; Betamethasone; Emergency department; Randomized, controlled trial

Comparaison entre la bétaméthasone intramusculaire et la prednisone orale pour prévenir les rechutes d’asthme aigu

OBJECTIF : Comparer le taux de rechute après l’injection intramusculaire d’une seule dose d’un corticostéroïde à action...
A
cute exacerbations of asthma are a common presenta-
tion to emergency departments (EDs). Most patients
can be adequately treated and safely discharged home
with the appropriate medications and follow-up. Recent studies
and a systematic review have shown the benefit of a course of
corticosteroids following discharge from the ED in reducing
the risk of relapse (1-3). However, the relapse rate at 21 days
remains as high as 25% despite the use of corticosteroids (4).

Patients with asthma who use the ED during acute exacer-
bations are thought to have high indexes of denial and poor
compliance, thus leading to poor control of their disease.
Compliance with pulmonary medications has been reported
to be as low as 30% (5). Twelve per cent to 22% of patients
leaving the ED do not fill their prescriptions (6,7). They are
often given complex regimens of corticosteroids involving
multiple tablets, which may further decrease compliance. A
single depot injection of corticosteroid administered at the
time of discharge may bypass these compliance issues and
lead to a reduction in relapse rates. McNamara and Rubin (8)
compared intramuscular methylprednisone with placebo af-
fter discharge for acute asthma and found a significant re-
duction in relapse rates. There are few studies directly
comparing intramuscular with oral corticosteroids after
exacerbations (9-11).

We undertook this pilot study to compare the relapse rates
in patients with acute exacerbations of asthma discharged from
the ED who had been given a single intramuscular injec-
tion of betamethasone 12 mg/day or prednisone 50 mg/day for
seven days. Our primary end point was the relapse rate at
days 7 and 21, and secondary end points were symptom
score, peak flows and adverse effects.

PATIENTS AND METHODS

Patients: This randomized, double-blind, controlled clinical
trial was conducted at two hospitals in Calgary, Alberta. The
EDs of these hospitals provide 24 h coverage in a community
of 853,711 people (12). From June 1997 to August 1999, ED
physicians were asked to refer patients treated in the ED
base between the two groups, to the exception of the duration of the asth-
me (15.5 ans contre 21.2 respectivement) and of the utilization of
corticostéroïdes en aérosol (46 % contre 64.3 % respectivement)
(P=0.05). Selon l’analyse fondée sur le principe de vouloir traiter,
le taux de rechute pour la bétaméthasone et la prednisone au
7e jour a été de 14,9 % (13 patients sur 87) et de 25 % (21 pa-
tients sur 84) respectivement (P=0.1) et au 21e jour, de 36,8 %
(32 patients sur 87) et de 31 % (26 patients sur 84) respecti-
ment (P=0.4). Aucune différence n’a été enregistrée quant à la
cote des symptômes, au débit de pointe et aux effets indésirables
entre les deux groupes au 7e et au 21e jour.

CONCLUSION: L’injection intramusculaire d’une seule dose
de bétaméthasone intramusculaire de 12 mg s’est avérée sûre et aussi efficace
que la prednisone pour prévenir les rechutes d’asthme aigu. Une
tendance à une réduction du taux de rechute a même été obser-
vée au 7e jour. Aussi la bétaméthasone intramusculaire peut-elle
remplacer efficacement la prednisone chez les patients sélec-
tionnés, traités pour une poussée d’asthme et renvoyés du ser-
dom de prédilection pour persistance ou ag-
gravation des symptômes d’asthme.

RÉSULTATS : Cent soixante et onze patients ont participé à
l’étude ; 87 ont reçu au hasard ou bien une injection intramusculaire de bétamé-
thasone de 12 mg et des capsules placebo ou bien une injection
intramusculaire placebo et des capsules de prednisone de 50 mg
à prendre tous les jours pendant sept jours. Au bout du 7e et du
21e jour, les chercheurs ont communiqué avec les patients pour
savoir s’ils avaient fait des rechutes. On entendait par rechute
une poussée d’asthme et ayant obtenu leur congé du service
d’urgence.

Can Respir J Vol 8 No 3 May/June 2001
These guidelines recommend prednisone 30 mg/day to 60 mg/day for seven to 14 days. Betamethasone was chosen as the depot steroid because of its potent anti-inflammatory effect and long duration of action. The relative anti-inflammatory potency of betamethasone to that of prednisone is 25 to 4, and its half-life is 36 to 72 h (14).

After consent was obtained, a kit was opened by a nurse who was not involved with the study patient. This nurse drew up the 2 mL solution and placed a translucent sleeve over the syringe to obscure the medication but to allow the gradation to be seen. The primary nurse involved with the patient was given the covered syringe and capsules, and administered the intramuscular injection. The patients were instructed to take the study capsules daily for the next seven days.

Each patient was given a peak flow meter (Pocketpeak, Hudson Respiratory Care Inc, USA) and instructed on its use. They were asked to record the best of three morning and three evening peak flow readings for the 21 days.

The discharge instructions were not standardized. Recommendations on the use of current medications including beta2-agonists, inhaled corticosteroids and theophylline were left to the discretion of the treating ED physician. A card containing information on the study and a contact number for the research coordinator was given to each patient.

Data collection: The primary end point was the relapse rate at days 7 and 21. Patients were contacted by telephone on day 7 and day 21 by a study coordinator blinded to the treatment allocation, and asked if they had sought treatment for their asthma since the initial ED visit. Patients were considered lost to follow-up if multiple telephone calls on three separate days were unsuccessful. A relapse was defined as an unscheduled visit to the ED, medical clinic or the patient’s own family physician for treatment of continuing or worsening symptoms of asthma. A visit to the family physician made after the patient’s discharge from the ED for follow-up was not considered to be a relapse if, at the time of the visit, the patient was asymptomatic or improving, and would not ordinarily have visited a physician. Before unblinding, all instances of suspected relapse were reviewed by two of the investigators.

Patients were also asked about symptoms, peak flows and adverse effects. A simplified asthma symptom score was obtained at days 7 and 21 consisting of shortness of breath, cough, wheeze, activity limitation and sleep disturbance. The patients were asked to give a score of 1 to 10 for each symptom, with 1 indicating the absence of the symptom and 10 indicating the most severe symptom. The best morning and evening peak flow readings were recorded for the 21 days.

Statistical analysis: Continuous variables were reported as the mean ± SD. The primary analysis was based on the intention-to-treat principle. Two-tailed tests were used for continuous variables and analysis for categorical variables. All results were considered significant at P<0.05.

This study was designed as a pilot to ensure that there was no dramatic difference between the two groups, and the ability to show a twofold difference in the relapse rate after asthma exacerbation. A sample size of approximately 180 patients was estimated using the following assumptions: 80% power and a 95% CI to show a difference between relapse rates of 40% and 20%.

RESULTS

During the study, 176 patients with acute asthma agreed to participate in the trial. After random assignment, five patients were subsequently excluded: three patients required hospitalization before ED discharge; one was discovered to be on chronic oral prednisone; and one refused the injection (Figure 1).

Of the remaining 171 patients, 84 received prednisone and 87 received betamethasone. At day 7, three patients were lost...
to follow-up — two in the prednisone group and one in the betamethasone group. By day 21, 12 patients were lost to follow-up — four in the prednisone group and eight in the betamethasone group. At the completion of the study, follow-up information was available for 159 patients (93%).

The primary analysis of relapse rates was based on the 171 appropriately enrolled patients. The baseline characteristics of the two groups are shown in Tables 1, 2 and 3. Patients allocated to prednisone had a longer duration of asthma (21.2 versus 15.5 years, \(P=0.002\)) and were more likely to be on regular inhaled corticosteroids (64.3% versus 46%, \(P=0.02\)). Age, sex, smoking status, markers of severity (ED visits, hospitalization, intensive care unit admissions and intubation) and baseline peak flows were similar between the two groups. The use of intravenous or oral steroids in the ED before enrolment did not differ significantly between the two groups.

The relapse rates for the two groups at days 7 and 21 are shown in Table 4. At day 7 in the prednisone group, 19 patients had relapsed and two had been lost to follow-up (21 of 84 [25%]). In the betamethasone group, 12 patients relapsed and one was lost to follow-up (13 of 87 [14.9%]). The seven-day relapse rate in the betamethasone group was 60% of that in the prednisone group, but the difference did not reach statistical significance (\(P=0.1\)).

At day 21 in the prednisone group, 22 patients had relapsed and four were lost to follow-up (26 of 84 [31%]). In the betamethasone group, 24 had relapsed and eight were lost to follow-up (32 of 87 [36.8%]). The difference was not statistically significant (\(P=0.4\)).

Secondary outcomes included symptom scores, peak flows and adverse effects. Symptom scores for patients who had not relapsed and were available for follow-up at days 7 and 21 are shown in Table 5. Some patients refused to provide symptom scores. For example, at day 21 in the betamethasone group, 24 patients had relapsed, eight were lost to follow-up and seven did not provide symptom scores; therefore, scores are provided for 48 patients or 55% of the original 87 randomly assigned patients. No significant differences were seen between the two groups at either day 7 or day 21.

The mean peak flow for weeks 1 and 3 for each group was calculated using the average of the best morning and evening readings available from patients who had not relapsed, and with at least five readings during the week (Table 6). There were no significant differences between the two groups.

All of the patients randomly assigned to receive prednisone reported taking all seven capsules; 95% of the patients in the betamethasone group completed the entire course. Fifty-six per cent of the prednisone group and 61% of the betamethasone group reported no adverse effects (\(P=0.5\)). The most common adverse effects reported were insomnia and nausea (prednisone: five of 84 and six of 84 patients, respectively; betamethasone: nine of 87 and seven of 87 patients, respectively).

### TABLE 2
**Baseline characteristics: Asthma history of 171 patients with acute exacerbations of asthma**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Prednisone (n=84)</th>
<th>Betamethasone (n=87)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous oral steroid use (%)</td>
<td>65 (77)</td>
<td>66 (76)</td>
<td></td>
</tr>
<tr>
<td>Previous ED visits (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Three</td>
<td>49 (59)</td>
<td>54 (62)</td>
<td></td>
</tr>
<tr>
<td>One to three</td>
<td>29 (35)</td>
<td>28 (32)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>5 (6)</td>
<td>5 (6)</td>
<td></td>
</tr>
<tr>
<td>Previous hospitalizations (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Three</td>
<td>25 (30)</td>
<td>25 (29)</td>
<td></td>
</tr>
<tr>
<td>One to three</td>
<td>25 (30)</td>
<td>29 (33)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>33 (40)</td>
<td>33 (38)</td>
<td></td>
</tr>
<tr>
<td>Previous ICU admission (%)</td>
<td>14 (17)</td>
<td>9 (10)</td>
<td></td>
</tr>
<tr>
<td>Previous intubation (%)</td>
<td>4 (5)</td>
<td>5 (6)</td>
<td></td>
</tr>
<tr>
<td>Asthma care (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family physician</td>
<td>58 (69)</td>
<td>64 (74)</td>
<td></td>
</tr>
<tr>
<td>Respirologist</td>
<td>9 (11)</td>
<td>15 (17)</td>
<td></td>
</tr>
<tr>
<td>Peak flow meter (%)</td>
<td>39 (46)</td>
<td>40 (46)</td>
<td></td>
</tr>
<tr>
<td>Peak flow action plan (%)</td>
<td>23 (27)</td>
<td>30 (35)</td>
<td></td>
</tr>
</tbody>
</table>

\(P\) values given are for those less than 0.05. ED Emergency department; ICU Intensive care unit

### TABLE 3
**Baseline medications and emergency department (ED) characteristics of patients with acute exacerbations of asthma**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Prednisone (n=84)</th>
<th>Betamethasone (n=87)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short acting</td>
<td>80 (95)</td>
<td>84 (97)</td>
<td></td>
</tr>
<tr>
<td>Long acting</td>
<td>5 (6)</td>
<td>2 (2)</td>
<td></td>
</tr>
<tr>
<td>Inhaled corticosteroid</td>
<td>54 (64)</td>
<td>40 (46)</td>
<td>0.02</td>
</tr>
<tr>
<td>Theophylline</td>
<td>3 (4)</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Leukotriene receptor antagonist</td>
<td>1 (1)</td>
<td>2 (2)</td>
<td></td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>4 (5)</td>
<td>4 (5)</td>
<td></td>
</tr>
<tr>
<td>Nedocromil</td>
<td>0</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>ED systemic corticosteroids (%)</td>
<td>58 (69)</td>
<td>68 (78)</td>
<td></td>
</tr>
<tr>
<td>Initial ED peak expiratory flow rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) (L/min)</td>
<td>270 (103)</td>
<td>261 (104)</td>
<td></td>
</tr>
<tr>
<td>% predicted peak expiratory flow rate (SD)</td>
<td>50 (17)</td>
<td>50 (19)</td>
<td></td>
</tr>
</tbody>
</table>

\(P\) values given are for those less than 0.05

### Table 4
**Relapse rates at day 7 and day 21 of patients with acute exacerbations of asthma**

<table>
<thead>
<tr>
<th></th>
<th>Prednisone (n=84)</th>
<th>Betamethasone (n=87)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 7 (%)</td>
<td>21 (25)</td>
<td>13 (14.9)</td>
<td>0.1</td>
</tr>
<tr>
<td>Day 21 (%)</td>
<td>26 (31)</td>
<td>32 (36.8)</td>
<td>0.4</td>
</tr>
</tbody>
</table>
Betamethasone and prednisone in asthma relapse prevention

### TABLE 5
Asthma symptom score* at day 7 and day 21 of patients with acute exacerbations of asthma

<table>
<thead>
<tr>
<th>Symptom (mean [SD])</th>
<th>Prednisone</th>
<th>Betamethasone</th>
<th>Prednisone</th>
<th>Betamethasone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients (%)</td>
<td>63 (75)</td>
<td>70 (80)</td>
<td>58 (69)</td>
<td>48 (55)</td>
</tr>
<tr>
<td>Shortness of breath 4.3 (2.3)</td>
<td>4.3 (2.3)</td>
<td>3.8 (2.4)</td>
<td>3.8 (2.4)</td>
<td></td>
</tr>
<tr>
<td>Cough 4.7 (2.9)</td>
<td>4.7 (2.9)</td>
<td>3.4 (2.4)</td>
<td>2.8 (2.2)</td>
<td></td>
</tr>
<tr>
<td>Wheeze 4.4 (2.4)</td>
<td>3.9 (2.4)</td>
<td>3.4 (2.3)</td>
<td>3.4 (2.5)</td>
<td></td>
</tr>
<tr>
<td>Activity limitation 3.4 (2.7)</td>
<td>3.4 (2.7)</td>
<td>2.2 (2.1)</td>
<td>2.1 (2.3)</td>
<td></td>
</tr>
<tr>
<td>Sleep disturbance 3.2 (3.2)</td>
<td>3.7 (3.1)</td>
<td>2.8 (2.7)</td>
<td>2.9 (2.7)</td>
<td></td>
</tr>
</tbody>
</table>

*10-point scale: 1 equals absence of the symptom, 10 equals most severe symptom

### DISCUSSION

Although oral and intramuscular corticosteroids for the treatment of acute exacerbations of asthma after discharge from the ED have been shown to be effective, there are few studies involving direct comparisons between the two regimens. Hoffman and Fiel (9) compared injected methylprednisolone sodium acetate 80 mg with oral prednisone in 17 patients with acute asthma and found no difference in relapse at seven days. In 1998, a year after the initiation of the present study, Schuckman et al (11) reported a trend toward a reduced relapse rate at seven days (9.0% versus 14.5%) in 154 patients discharged from the ED for acute asthma given a single dose of intramuscular triamcinolone 40 mg versus five days of prednisone. Our trial with 171 patients is the largest study directly comparing intramuscular with oral corticosteroids for acute exacerbations of asthma after discharge from the ED.

We found a reduced relapse rate at day 7 in patients given intramuscular betamethasone compared with those given prednisone, although the results were not statistically significant. At the time of completion of our trial, Rowe et al (15) reported that the addition of inhaled budesonide to a short course of prednisone in patients discharged from the ED for acute asthma significantly reduced the relapse rate at 21 days. In this study, at baseline, the patients in the prednisone group were more likely to be on maintenance inhaled corticosteroids (64% versus 46%), and this may have resulted in a decreased relapse rate in the prednisone group, thus reducing the likelihood of finding a statistically significant difference. On the other hand, the higher use of inhaled corticosteroids and the longer duration of asthma in the prednisone group might suggest a more severe subset of asthma patients and, therefore, a higher probability of relapse; however, other markers of severity (previous oral corticosteroids, ED visits, hospitalizations and intensive care admissions) between the two groups were not significantly different.

The finding of a reduced relapse rate at day 7 with intramuscular corticosteroid, although not statistically significant, is similar to the results of Schuckman et al (11). Although sizable numbers of patients were recruited (154 patients in the study by Schuckman et al and 171 patients in the present study), both studies might have been limited by the small sample size. However, if our results are combined with those of Schuckman et al (11), the relapse rate at day 7 achieves statistical significance (P=0.05), favouring intramuscular corticosteroid. Adding the 17 patients from Hoffman and Fiel (9) reduces the P value to 0.03. Analysis of the aggregate studies suggests that intramuscular corticosteroid may be more effective than oral prednisone in preventing the relapse of acute exacerbations of asthma at day 7. At day 21, there was no difference in relapse rate between the two groups. This would suggest that if intramuscular betamethasone was effective, it would only protect against early relapse. This may reflect the pharmacokinetics of betamethasone, which has a half-life of 36 to 72 h when given orally. When given intramuscularly, the half-life and duration of action are less well described. The 12 mg dose of betamethasone was chosen to maximize the anti-inflammatory effect and minimize pain at the injection site. This dose might have been low, and a larger dose might have shown a sustained reduction in relapse rate at 21 days. Alternatively, 21 days after an exacerbation, the maintenance medications, environmental conditions and underlying control may become more important in determining the tendency to relapse – hence, the finding of similar relapse rates further from the original exacerbation.

Our relapse rates in the prednisone group (25% and 31%) were higher than those reported in previous studies. At days 7 to 14, relapse rates between 10% and 17% have been reported (1,8,16); at day 21, the rates range from 20% to 25% (1,4). In the inhaled budesonide study, Rowe et al (15) found a relapse rate of 24.5% at day 21 in patients given only prednisone.

### TABLE 6
Peak flows for weeks 1 and 3 of patients with acute exacerbations of asthma

<table>
<thead>
<tr>
<th>Week 1</th>
<th>Week 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone*</td>
<td>60 (71%)</td>
</tr>
<tr>
<td>Prednisone*</td>
<td>63 (72%)</td>
</tr>
</tbody>
</table>

*Nonrelapsed patients with data available. Mean peak flow calculated from the available best morning and evening readings. PEFR Peak expiratory flow rate
A selection bias may account for the higher relapse rate because we relied on ED physicians to refer patients. A review of ED records from the two hospitals over the study period revealed that we were able to enrol only 6% of patients treated for acute asthma. Some of those not referred presumably met the exclusion criteria, but it is likely that a large percentage of eligible patients were not enrolled. Compared with the patients in the inhaled budesonide study by Rowe et al (15), patients in the present study reported a higher prevalence of past ED treatment (94% versus 59%), past hospitalizations (61% versus 38%) and previous use of oral corticosteroids (77% versus 30%). Compared with the study by Chapman et al (1), our patients reported a higher prevalence of past hospitalizations (61% versus 34%) and previous use of oral corticosteroids (77% versus 30%). Our study population appears to include a higher percentage of patients with worse indexes of underlying control and compliance.

It is important to note that, in practice, only a prescription for prednisone is given at the time of discharge from the ED. In the present study, we provided the prednisone that presumably would lead to higher compliance and reduced relapse. Thus, the relapse rate in the prednisone group is probably an underestimate of what occurs in actual clinical practice.

There are a number of limitations of the present study. As noted earlier, our study population represented approximately 6% of the patients treated in the ED for asthma during the study period and, therefore, may not be representative of all patients with acute asthma. Our patients had high rates of previous ED visits, hospitalizations and previous oral corticosteroid use, which suggests a more severe subset of asthma patients. Secondly, discharge instructions were not standardized by protocol. Third, relapse was assessed by telephone contact only. We did not perform in-person assessments or review all medical records to ensure that those patients who reported being improved had not relapsed.

CONCLUSIONS

This study was designed as a pilot study to detect major differences between treatment with betamethasone and prednisone. Further studies with a larger number of patients are needed to confirm the proposed advantage of an intramuscular corticosteroid to prevent the relapse of acute asthma.

Our study suggests that the administration of a single dose of intramuscular betamethasone 12 mg compared with oral prednisone after ED treatment of acute asthma is safe and may lead to an improved outcome at day 7. Although the relapse rates between the two groups were equivalent at day 21, the ability to prevent early relapse would provide a window of opportunity to optimize the outpatient management of asthma. Close follow-up with a physician after ED treatment, education and the use of inhaled corticosteroids may prevent subsequent relapse. In selected ED patients with a high risk for relapse and poor compliance, a single dose of intramuscular betamethasone after ED treatment for acute asthma may prove to be an effective alternative to a prescription for prednisone.

ACKNOWLEDGEMENTS: Supported by a grant by Research and Development of the University of Calgary, Calgary, Alberta. Betamethasone (Celestone Soluspan) was supplied by Schering Canada Inc, Pointe-Claire, Quebec. The purchase of peak flow meters was provided by Boehringer Ingelheim (Canada) Limited, Burlington, Ontario. The authors thank the staff of the emergency and respiratory therapy departments of the Rockyview General Hospital and the Peter Lougheed Center for their support and contribution to this study, and Mrs Diane Phillips-Reeder and the department of pharmacy for their preparation of the study medications.

REFERENCES

15. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Iacono J. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA 1999;281:2119-26.